Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vigil Neuroscience, Inc. - Common Stock (NQ: VIGL ) 3.510 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Vigil Neuroscience, Inc. - Common Stock < Previous 1 2 Next > Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus July 13, 2023 Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. Via MarketBeat Topics Retirement Exposures Pension Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference June 01, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update May 10, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors May 09, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) May 08, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101 March 30, 2023 Company remains on track to report interim data from Phase 2 trial in the second half of 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at Stifel 2023 CNS Days March 22, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update March 21, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting March 02, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference January 03, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team December 15, 2022 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP December 14, 2022 First-ever interventional trial for patients with ALSP, a rare and rapidly progressing neurological disease with significant unmet medical need From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022 November 28, 2022 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update November 10, 2022 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at Upcoming Investor Conferences November 07, 2022 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP November 02, 2022 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP November 01, 2022 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne Bruhn, Ph.D. July 28, 2022 From Vigil Neuroscience, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.